What is OmniLytics?
OmniLytics, Inc. is at the forefront of sustainable biotechnology, specializing in eco-friendly bacteriophage solutions. These advanced biological agents are designed to combat harmful pathogens across key sectors including crop science, food safety, and animal health. The company's AgriPhage product line offers a potent, chemical-free alternative to traditional pesticides and antibiotics, aiming to boost agricultural yields and mitigate the economic impact of bacterial diseases. Beyond its product offerings, OmniLytics leverages its state-of-the-art GMP manufacturing facility to provide contract manufacturing services for phage-based products, ensuring rigorous quality control and production standards. The company's commitment to ecological principles and sustainable practices positions it as an innovator in revolutionizing bacterial disease management.
How much funding has OmniLytics raised?
OmniLytics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for OmniLytics?
The substantial backing OmniLytics has received, particularly the recent strategic investment, signals a strong market validation and positions the company for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development into novel bacteriophage applications, expand manufacturing capabilities, and broaden its commercial reach. OmniLytics is poised to solidify its leadership in providing safe, effective, and environmentally conscious alternatives to conventional chemical treatments, addressing growing global demands for sustainable agricultural and health solutions.
See full OmniLytics company page
